Welcome to our dedicated page for Inogen SEC filings (Ticker: INGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inogen Inc (INGN) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a Nasdaq-listed medical technology issuer. Inogen files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with other required documents, providing detailed insight into its respiratory care business for the homecare setting.
In its periodic reports, Inogen presents financial statements and operating data covering sales and rental revenue, gross profit, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as net income or loss, cash flows, and balance sheet information. Supplemental tables may break out revenue by category, including business-to-business domestic and international sales and direct-to-consumer and rental activity, reflecting how its respiratory products reach patients and providers.
Current reports on Form 8-K document material events, such as the release of quarterly financial results and certain leadership or governance changes. For example, Inogen has used Form 8-K to furnish press releases reporting results for quarters ended March 31, June 30, and September 30, 2025, and to describe appointments and designations of executive officers.
On Stock Titan, these filings are updated as they become available from EDGAR and are paired with AI-powered summaries that explain key points in accessible language. Users can quickly see what Inogen reports about its respiratory product portfolio, revenue mix between sales and rentals, operating trends, and significant corporate developments without reading every line of each document.
Investors researching INGN can use this page to access 10-K and 10-Q filings for a structured view of Inogen’s financial condition and risk disclosures, and Form 8-K filings for timely updates on results of operations and notable corporate events, all supported by AI-generated highlights.
Inogen, Inc. announced a leadership transition and new executive hires while reaffirming its first quarter and full-year 2026 financial outlook. Jason Richardson will become Executive Vice President, Chief Financial Officer and Treasurer on April 6, 2026, succeeding Michael Bourque, who will remain as a senior advisor through June 30, 2026.
Richardson’s employment agreement includes a $525,000 annual base salary, a 70% target bonus, $100,000 in cash sign-on and retention bonuses, and equity awards covering 200,000 shares split between time-based and performance-based restricted stock units, with potential overachievement up to 150,000 PSUs. The agreement provides severance and COBRA-related benefits if he is terminated without cause or resigns for good reason, with enhanced salary continuation during a defined change-of-control period.
Inogen also appointed Dominic Hulton as Chief Marketing Officer effective April 1, 2026, and recently added Corey Moritz as Vice President, U.S. Business to Business Sales. The company highlights these appointments as supporting its next phase of growth and notes continued use of its investor relations website for material disclosures.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A reporting zero beneficial ownership of Inogen Inc common stock. The filing states an Amount beneficially owned: 0 and Percent of class: 0% as reported in the amendment dated 03/13/2026. The filing explains an internal realignment and disaggregation of Vanguard subsidiaries in accordance with SEC Release No. 34-39538 (January 12, 1998), noting certain subsidiaries now report separate beneficial ownership. The signature on the amendment is dated 03/27/2026 and is signed by Ashley Grim, Head of Global Fund Administration.
Inogen Inc executive Mary E. Wright, the VP and Chief Accounting Officer, reported several equity compensation transactions. On March 1, 2026, multiple restricted stock unit tranches, including 1,755, 2,750 and 3,001 units, were exercised or converted into common stock at no cash cost. She also received common stock grants of 1,500 and 1,351 shares, while 675, 520, 1,058 and 1,155 shares of common stock at $6.10 were withheld to cover tax liabilities on the vesting awards. A separate grant of 8,000 restricted stock units was awarded on February 27, 2026, with vesting over several years subject to continued service.
Inogen Inc executive Jennifer M. Yi Boyer reported multiple equity award events. On February 27, 2026, she received a grant of 32,500 restricted stock units, each representing one share of common stock. These units vest in three equal annual installments starting March 1, 2027, subject to continued service.
On March 1, 2026, restricted stock units previously granted fully vested or were earned based on 2025 financial performance, and were converted into common shares. In connection with these vestings, blocks of shares were withheld at $6.10 per share to cover tax liabilities. After these transactions, she directly owned 26,747 shares of Inogen common stock.
Inogen’s Chief Commercial Officer Gregoire Ramade reported equity compensation activity involving restricted stock units and common shares. On March 1, 2026, 13,005 restricted stock units were exercised into 13,005 shares of common stock, and 6,022 shares were withheld at $6.10 per share to cover tax liabilities linked to a vesting award.
On February 27, 2026, Ramade received a new grant of 20,000 restricted stock units, each representing one share of Inogen common stock. One-third of this grant is scheduled to vest on March 1, 2027, with the remaining units vesting in equal annual installments on the same date in subsequent years, subject to continued service.
Inogen Inc executive Kevin P. Smith reported multiple equity compensation transactions. On February 27, 2026, he received a grant of 35,000 restricted stock units (RSUs), each representing the right to receive one share of Inogen common stock, subject to multi-year vesting based on continued service.
On March 1, 2026, 14,005 RSUs were exercised into common stock at no cost, and he was also awarded 1,500 shares of common stock at $6.10 per share. To cover tax withholding related to vested RSUs, 6,276 shares of common stock were disposed of at $6.10 per share. After these transactions, he directly held 22,007 shares of common stock and a remaining RSU balance as reported.
Inogen Inc EVP, CFO & Treasurer Michael J. Bourque reported multiple equity transactions. He acquired common stock through the vesting and exercise of restricted stock units on March 1, 2026, along with additional stock awards, and had shares withheld to satisfy tax obligations.
Several restricted stock unit awards converted into common stock at a stated price of $6.10 per share for tax purposes, with disposals labeled as tax-withholding transactions rather than open-market sales. After these transactions, he directly held 94,596 shares of Inogen common stock and 39,000 restricted stock units, each unit representing a contingent right to one share.
Inogen Inc CEO and President Kevin Raymond Merrill Smith reported multiple equity award transactions. On February 27, 2026, he received a grant of 90,000 restricted stock units, each representing a contingent right to one Inogen common share. Subject to continued service, one-third vests on March 1, 2027, with additional one-third portions vesting annually on the same date in subsequent years.
On March 1, 2026, performance-based and time-based restricted stock units vested, leading to share acquisitions and related tax-withholding dispositions. Vested awards included 28,334 and 30,012 shares from restricted stock units earned for 2025 financial performance, plus common stock awards of 685 and 32,725 shares. To cover tax liabilities on these vestings, the company withheld 16,374, 13,700, and 14,511 shares of common stock.
Inogen, Inc. files its annual report describing a respiratory-focused medical technology business built around portable oxygen concentrators, the Simeox airway-clearance device, Voxi 5 stationary oxygen concentrators, and Aurora CPAP masks. The company targets chronic respiratory conditions such as COPD, bronchiectasis and obstructive sleep apnea.
In 2025, Inogen generated $209.8 million of revenue in the United States, with about 45.1% from business-to-business sales, 29.5% from direct-to-consumer sales, and 25.4% from direct-to-consumer rentals. Approximately 39.8% of total 2025 revenue came from outside the United States, sold through distributors and large house accounts in 70 countries.
The report highlights a strategic collaboration with Yuwell to distribute Voxi 5 and Aurora masks in the United States and certain Asian markets, and the 2023 acquisition of Physio‑Assist, which added Simeox and expanded into airway clearance. Rental revenue depends heavily on Medicare programs, which supplied 61.9% of 2025 rental revenue and 9.5% of total revenue. As of December 31, 2025, Inogen employed 753 people worldwide and emphasizes innovation, regulatory compliance, and clinical evidence to support adoption of its products.
Inogen, Inc. reported modest growth but sharply better profitability for 2025 and announced a new share repurchase program. Full-year 2025 revenue rose 3.9% to $348.7 million, driven by 18.4% growth in international sales, while U.S. sales and rentals declined.
Net loss narrowed to $22.7 million from $35.9 million, and adjusted EBITDA turned positive at $2.7 million versus a $9.5 million loss in 2024. Cash, marketable securities, and restricted cash totaled $120.9 million with no debt. The board authorized a share repurchase program of up to $30 million through December 31, 2027.
For 2026, Inogen expects revenue of $366–$373 million, about 6% growth at the midpoint, and remains focused on further adjusted EBITDA improvement. Management highlighted new product launches, a strong balance sheet, and a strategic collaboration in China as key supports for future growth.